Sanofi (NASDAQ:SNY – Free Report) had its target price boosted by Argus from $55.00 to $60.00 in a research report sent to investors on Friday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.
Sanofi Stock Performance
NASDAQ:SNY opened at $52.09 on Friday. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The business’s fifty day moving average is $49.29 and its 200 day moving average is $48.66. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $131.93 billion, a price-to-earnings ratio of 26.18, a PEG ratio of 1.63 and a beta of 0.59.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 earnings per share. Research analysts predict that Sanofi will post 4.14 EPS for the current year.
Institutional Investors Weigh In On Sanofi
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
- Five stocks we like better than Sanofi
- Trading Halts Explained
- Survey: Top 175 Fittest Retirement Locations in America
- P/E Ratio Calculation: How to Assess Stocks
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Investing In Automotive Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.